Te Pātaka Whaioranga – Pharmac is pleased to confirm
that naloxone injections will now be supplied to the New
Zealand Needle Exchange Programme, to ensure it is available
in the community to treat opioid
overdoses.
“Naloxone quickly reverses an overdose of
drugs such as heroin, oxycodone, fentanyl or synthetic
opioids. We have heard from groups like the New Zealand Drug
Foundation that there’s a real need for it to be available
at needle exchange sites,” says Pharmac’s Director,
Pharmaceuticals, Geraldine MacGibbon.
In late
September Pharmac was made aware of
being sold illegally. It
was reported they contained a synthetic opioid which is
about six times more potent that fentanyl and resulted in at
least one death and several hospitalisations.
“We
know naloxone can reverse the life-threatening effects of
many synthetic opioids, so enabling needle exchange sites to
be able to hold supplies will help those staff with their
efforts to reduce the harm associated with opioid use in the
community.”
The Executive Director of the Drug
Foundation, Sarah Helm says the arrival of naloxone into
needle exchanges is great news. “Opioids are already one
of the leading causes of overdose deaths in New Zealand and
there are potent opioids like nitazenes now appearing in our
drug supply. Having naloxone available will save
lives.”
Advertisement – scroll to continue reading
Earlier this year Medsafe made amendments to
the classification of naloxone, to allow the ampoules with
needles or syringes, or pre-filled syringes, to be held by
needle exchange sites without a prescription. Pharmac then
reached an agreement with medicines distributor Onelink to
add naloxone to its deliveries direct to community health
organisations.
Pharmac received an application for the
naloxone nasal spray (branded as Nyxoid) at the beginning of
2023 and will be seeking clinical advice from our expert
advisors regarding its potential future
funding.
© Scoop Media



















Discussion about this post